Related references
Note: Only part of the references are listed.Emerging Immunotherapies in the Treatment of Brain Metastases
Edwin Nieblas-Bedolla et al.
ONCOLOGIST (2021)
Factors influencing early postoperative complications following surgery for symptomatic spinal metastasis: a single-center series and multivariate analysis
Patrick Schuss et al.
NEUROSURGICAL REVIEW (2020)
Preoperative Survival Prediction in Patients With Glioblastoma by Routine Inflammatory Laboratory Parameters
Daniela Pierscianek et al.
ANTICANCER RESEARCH (2020)
Hypoxia, Inflammation and Necrosis as Determinants of Glioblastoma Cancer Stem Cells Progression
Marco Papale et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
Andressa S. Laino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Arabinogalactan Utilization by Bifidobacterium longum subsp. longum NCC 2705 and Bacteroides caccae ATCC 43185 in Monoculture and Coculture
Yan Wang et al.
MICROORGANISMS (2020)
Comorbidity Burden and Presence of Multiple Intracranial Lesions Are Associated with Adverse Events after Surgical Treatment of Patients with Brain Metastases
Matthias Schneider et al.
CANCERS (2020)
Prognostic value of a novel scoring system using inflammatory response biomarkers in non-small cell lung cancer: A retrospective study
Yan Wang et al.
THORACIC CANCER (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study
Yixi Wang et al.
FRONTIERS IN ONCOLOGY (2019)
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy
Mehmet A. Bilen et al.
CANCER (2019)
Prognostic value of the fibrinogen-to-platelet ratio as an inflammatory and coagulative index in patients with gastric cancer
Kohei Wakatsuki et al.
SURGERY TODAY (2019)
Brain metastases
Achal Singh Achrol et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Platelet-to-lymphocyte ratio in peripheral blood: A novel independent prognostic factor in patients with melanoma
Yalong Qi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery
Mudit Chowdhary et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study
Ryckie G. Wade et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer
Uiju Cho et al.
PLOS ONE (2018)
Elevated C-reactive protein and white blood cell count at admission predict functional outcome after non-aneurysmal subarachnoid hemorrhage
Patrick Schuss et al.
JOURNAL OF NEUROLOGY (2018)
Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma
Leonardo S. Lino-Silva et al.
MELANOMA RESEARCH (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor
Yoko Ishii et al.
PATHOLOGY INTERNATIONAL (2017)
Systemic Inflammatory Markers as Prognostic Factors in Stage IIA Colorectal Cancer
Byung Kwan Park et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review
Shiva Shrotriya et al.
PLOS ONE (2015)
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer
Graeme J. K. Guthrie et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients
Praveen Ravishankaran et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2011)
Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study
Kristine H. Allin et al.
BREAST CANCER RESEARCH (2011)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
Stephen Kaptoge et al.
LANCET (2010)
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
Isabelle Ray-Coquard et al.
CANCER RESEARCH (2009)
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)